The Latest Breaking News from GenBioPro

GenBioPro seeks to defend access to mifepristone in suit brought by attorneys general of Idaho, Missouri and Kansas

Oral arguments in the case come after June Supreme Court decision upholding access to abortion medication.

WASHINGTON — The Supreme Court gave itself more time on a decision expected Wednesday about a commonly used abortion drug, extending until Friday a temporary pause on a lower court ruling that would restrict availability of mifepristone.

The Supreme Court extended until Friday a temporary pause on a lower court ruling that would restrict availability of mifepristone.

GenBioPro, which makes a generic form of mifepristone, is suing the FDA seeking to preserve access to the drug amidst ongoing federal litigation.

Two federal judges issued dueling opinions Friday over the FDA's approval of an abortion drug more than 20 years ago.

Medication abortion now accounts for more than half of all abortions in the United States.

Medication abortion, which accounts for more than half of all abortions in the United States, has become more common since the Supreme Court overturned the federal right to abortion this summer.

The first significant stage of post-Roe abortion litigation is underway and focuses heavily on abortion pills. GenBioPro, a pharmaceutical company that makes the drug mifepristone, has asked a federal court to declare that West Virginia’s anti-abortion law is inconsistent with the Federal Drug Administration’s determination that the pill is safe…